Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A.

Kosei Ishimaru Masataka Ikeda Hiroko Deguchi Miyamoto Shun Furusawa Ko AbeMasatsugu WatanabeTakuya KanamuraSatoshi FujitaRyohei NishimuraTakayuki ToyoharaShouji MatsushimaTomoko KoumuraKen-Ichi YamadaHirotaka ImaiHiroyuki TsutsuiTomomi Ide

Published in: Journal of the American Heart Association (2023)

Combination therapy with deferasirox and CsA may be a clinically feasible and effective therapeutic approach for limiting I/R injury and ameliorating adverse cardiac remodeling after myocardial infarction.

Keyphrases

combination therapy
left ventricular
cell death
cancer therapy
mouse model
heart failure
adverse drug
atrial fibrillation